Navigation Links
Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
Date:2/15/2008

wo of these 65 patients received a dose of GVAX immunotherapy for prostate cancer comparable to that being evaluated in ongoing Phase 3 clinical trials. Of these 22 patients, 16 patients (73 percent) mounted an immune response to FLJ14668. These 16 patients achieved a median survival of 44.9 months. As previously reported, the median survival for all 22 patients in this treatment group was 35.0 months. Finally, of the 58 patients who were HLA-A24 genotype negative and therefore potentially able to mount anti-HLA-A24 specific antibody responses, 30 patients were found to be anti-HLA-A24 antibody positive. These 30 patients had a median survival of 43 months, compared to a median survival of 18 months in the patients who did not generate anti-HLA-A24 antibodies (p=0.05). Importantly, the apparent associations between the presence of these two specific antibody responses and survival were shown by multivariate analysis to be independent of both dose and duration of treatment.

"The findings being reported today indicate a potential association between two specific GVAX-induced antibody responses and patient survival, an association consistent with the proposed mechanism of action for this product. We look forward to expanding these findings in a prospective analysis of the sera of patients treated in our two randomized controlled Phase 3 trials," stated Peter K. Working, Ph.D., senior vice president of research and development at Cell Genesys. "Since GVAX immunotherapy for prostate cancer is a multi-antigen product that can induce a broad immune response, we believe we have a unique opportunity to identify the widest possible array of specific antibody responses that may be associated with clinical benefit."

Cell Genesys is currently evaluating GVAX immunotherapy for prostate cancer in two Phase 3 multicenter, randomized, controlled clinical trials. VITAL-1, which is fully enrolled with 626 patients, is designed to compare GVAX cancer immunotherapy to Taxo
'/>"/>

SOURCE Cell Genesys, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
2. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
3. CEL-SCI Corporation Reports First Quarter Financial Results
4. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
5. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
6. Cystic Fibrosis Foundation Reports Upward Trend for Key Health Outcomes
7. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
8. Study Reports Successful Cloning of Human Embryo Using Adult DNA
9. Schering-Plough Reports Top-Line Results of the IDEAL Study
10. Second Thoughts about Fluoride, Reports Scientific American
11. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Calif. and BRUSSELS ... AMGN ) and UCB (Euronext Brussels: UCB) today ... evaluating effect of RomosozUmab Compared with Teriparatide in ... fracture pReviously treated with bisphosphonatE therapy). The study ... significant difference in favor of romosozumab in the ...
(Date:9/1/2015)... Sept. 1, 2015 Emerus Holdings, a ... emergent, inpatient and diagnostic care in partnership with ... a definitive agreement to receive a strategic investment ... a leading health care investment firm. ... patient-centric acute episodic and ambulatory clinical services to ...
(Date:9/1/2015)... IRVINE, Calif. , Sept. 1, 2015  Edwards ... in the science of heart valves and hemodynamic monitoring, ... Fargo Healthcare Conference at the Hyatt Regency Boston in ... 9, 2015. Michael A. Mussallem , ... keynote lunch speaker followed by a company discussion with ...
Breaking Medicine Technology:Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 4Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 5Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 6Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 7Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 8Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 9Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 2Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 3
... /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (NASDAQ: ... emerging leader in the development, assembly, marketing and sale ... that the Company,s growing business earned a BBB+ Credit Rating ... "Zhongguancun Association") and was approved as a member of ...
... SHANGHAI, Feb. 28, 2012 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: ... China-based pharmaceutical and biotechnology research and development outsourcing company, ... results for the fourth quarter and full year ended ... host a conference call to discuss the results at ...
Cached Medicine Technology:Dehaier Medical Awarded Strong Credit Rating From Beijing Zhongguancun Enterprises Credit Promotion Association 2Dehaier Medical Awarded Strong Credit Rating From Beijing Zhongguancun Enterprises Credit Promotion Association 3ShangPharma to Report Fourth Quarter and Full Year 2011 Financial Results on March 13, 2012 2
(Date:9/1/2015)... ... September 01, 2015 , ... OncLive® ... hospital by U.S. News & World Report, to provide breaking news and information ... and marketing groups within OncLive, which provides oncologists resources and information?they need to ...
(Date:9/1/2015)... , ... September 01, 2015 , ... The Jerry Segal ... The ACE Club and Green Valley Country Club in Lafayette Hill, PA. Over the ... more than $13.5 million for programs and services designed to support patients and their ...
(Date:9/1/2015)... ... 01, 2015 , ... With former IBMers among its founding members, Inmar has ... more than 35 years ago. A pilot program begun by the company in 2014 ... just those intent on pursuing careers in these fields. The program is now open ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... the release of version 5.2 of the FirstSpirit Content Management System with new ... With the new version of FirstSpirit, companies will be well on their way ...
(Date:9/1/2015)... York (PRWEB) , ... September 01, 2015 , ... Zecurion, ... Zlock Mac , its groundbreaking new version of endpoint DLP developed specifically for Mac ... Mac, in which more than 100 IT and information security professionals had participated. The ...
Breaking Medicine News(10 mins):Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 2Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 3Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 3Health News:Zecurion Announces Endpoint Security for Mac 2
... Rose 12.8% to US$14.3 Million (RMB 107.7 ... Million) Compared to Third Quarter 2006, BEIJING, ... FFHL ), a manufacturer and distributor of,high-quality BOPET plastic film ... quarter and for the nine months,ended September 30, 2007 which ...
... Landmarks Mark First United Nations World Diabetes Day ... in blue to mark the,first United Nations-observed World Diabetes ... iconic buildings and sites. The landmarks will,light up the ... the global,symbol for diabetes. The Empire State Building, ...
... care begins to address the emotional needs of patients, ... Michigan Comprehensive Cancer Center shows that its important to ... found that a targeted intervention aimed at prostate cancer ... the spouse in physical and emotional quality of life. ...
... Made Us Who We Are" (p. 42). "There was at,the ... for the,challenges ahead. For the Sixties were also the glory ... Captain Jim Lovell," writes former,NBC News anchor Tom Brokaw, in ... cover package in which Newsweek looks back at,one of the ...
... Annual Meeting Examines ... Larger Disease, NEW ORLEANS, Nov. 11 Glaucoma has ... the 20th century, it was equated with,elevated intraocular pressure. Yet, ... factors have been,identified, suggesting that glaucoma can be broadly defined ...
... to care not a factor, study finds, urging greater outreach ... -- Living farther away from transplant centers doesn,t explain why ... than whites to be placed on the kidney transplant waiting ... that analyzed data on end-stage renal (kidney) disease patients in ...
Cached Medicine News:Health News:Fuwei Films Announces Third Quarter 2007 Financial Results 2Health News:Fuwei Films Announces Third Quarter 2007 Financial Results 3Health News:Fuwei Films Announces Third Quarter 2007 Financial Results 4Health News:Fuwei Films Announces Third Quarter 2007 Financial Results 5Health News:Fuwei Films Announces Third Quarter 2007 Financial Results 6Health News:World Diabetes Day Lights Up the Skyline 2Health News:World Diabetes Day Lights Up the Skyline 3Health News:Caregivers benefit from cancer support programs, U-M study finds 2Health News:NEWSWEEK: Media Lead Sheet/November 19, 2007 Issue (on newsstands Monday, November 12) 2Health News:NEWSWEEK: Media Lead Sheet/November 19, 2007 Issue (on newsstands Monday, November 12) 3Health News:NEWSWEEK: Media Lead Sheet/November 19, 2007 Issue (on newsstands Monday, November 12) 4Health News:NEWSWEEK: Media Lead Sheet/November 19, 2007 Issue (on newsstands Monday, November 12) 5Health News:Looking at Glaucoma as a Systemic Disease 2Health News:Looking at Glaucoma as a Systemic Disease 3Health News:Blacks in Poor Areas Less Likely to Be On Kidney Transplant Lists 2
... The SeedVac™ is a vacuum driven device designed to ... tube tip. Seeds are drawn into the clear tube ... the hand piece to create the vacuum. The prescribed ... the clear tube tip before being placed into the ...
MT-BT-5001-25 prostate seeding needle (set of 25 unloaded needles).,MT-BT-5001-P prostate seeding needle, pre-plugged and pre-sterilized, unloaded or for use with MEDTECs ASAP™ pre-load seeding...
... a myoma was performed with a cutting ... vaporization of myomas with the VaporTrode Vaporization ... tissue chips that obscure visibility. No tissue ... This unique design provides areas of high ...
... The 19 Fr. OES 4000 Nephroscope, with ... quality with outstanding durability. The lumbotome, for ... the telescopic bougies, allow safer access. The ... comprehensive range of grasping forceps and lithotripsy ...
Medicine Products: